-
公开(公告)号：US09943580B2
公开(公告)日：2018-04-17
申请号：US15023653
申请日：2014-09-11
申请人： STC.UNM , LEIDOS, INC
发明人： David S. Peabody , Bryce Chackerian , James Pannucci , Gabriel M. Gutierrez , Amy Rene Noe , Scott Budd Winram , Steve Chienwen Huang
CPC分类号： A61K39/015 , A61K35/76 , A61K39/39 , A61K2039/5256 , A61K2039/5258 , A61K2039/55566 , C07K2319/40 , C12N7/00 , C12N15/1037 , C12N2795/18122 , C12N2795/18123 , C12N2795/18134 , Y02A50/412
摘要： Embodiments are directed to malaria vaccines comprising a bacteriophage VLP displaying a heterologous peptide identified by affinity selection as an anti-malaria mimotope.
-
2.发明授权公开(公告)号：US09717783B2
公开(公告)日：2017-08-01
申请号：US13946562
申请日：2013-07-19
申请人： STC.UNM
CPC分类号： A61K39/12 , A61K2039/5258 , A61K2039/58 , C12N2710/20034 , C12N2795/18023 , C12N2795/18071
摘要： The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.
-
公开(公告)号：US10821167B2
公开(公告)日：2020-11-03
申请号：US16074886
申请日：2017-02-01
申请人： STC.UNM
发明人： Pamela Hall , Bryce Chackerian , David S. Peabody , Seth Michael Daly , Bradley Owen Elmore , Kathleen Triplett
IPC分类号： C12Q1/68 , A61K39/085 , A61P37/04 , A61P31/04 , A61K39/00
摘要： The present invention is directed to virus-like particles (VLPs) which are engineered to present epitopes from Staphylococcus aureus (SA), preferably autoinducing peptides (AIPs) which regulate quorum-sensing dependent virulence in this pathogen, or epitopes from SA toxins and leukocidins. These VLPs may be used to provide immunogenic compositions and efficacious vaccines. In a mouse model of SA dermonecrosis, vaccination with AIP-containing VLPs or SA toxin-containing VLPs induces protective immunity to limit the pathogenesis of SA infection and promote bacterial clearance.
-
公开(公告)号：US20190134170A1
公开(公告)日：2019-05-09
申请号：US16250514
申请日：2019-01-17
发明人： Alan Remaley , John T. Schiller , Marcelo Amar , Bryce Chackerian
摘要： A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.
-
5.发明申请公开(公告)号：US20170096456A1
公开(公告)日：2017-04-06
申请号：US15358786
申请日：2016-11-22
申请人： STC.UNM
发明人： Bryce Chackerian , David S. Peabody
IPC分类号： C07K14/005 , C12N7/00 , A61K39/12
CPC分类号： C07K14/005 , A61K39/12 , A61K47/6901 , A61K2039/5258 , A61K2039/55566 , C12N7/00 , C12N2710/20023 , C12N2710/20034 , C12N2795/18123
摘要： The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.
-
公开(公告)号：US10279019B2
公开(公告)日：2019-05-07
申请号：US15118143
申请日：2015-02-11
申请人： THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES , STC.UNM
发明人： Alan Remaley , John T. Schiller , Marcelo Amar , Bryce Chackerian
摘要： A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.
-
公开(公告)号：US20190038735A1
公开(公告)日：2019-02-07
申请号：US16074886
申请日：2017-02-01
申请人： STC.UNM
发明人： Pamela Hall , Bryce Chackerian , David S. Peabody , Seth Michael Daly , Bradley Owen Elmore , Kathleen Triplett
IPC分类号： A61K39/085 , A61P31/04 , A61P37/04
CPC分类号： A61K39/085 , A61K2039/52 , A61K2039/5258 , A61P31/04 , A61P37/04 , C12N2795/18123
摘要： The present invention is directed to virus-like particles (VLPs) which are engineered to present epitopes from Staphylococcus aureus (SA), preferably autoinducing peptides (AIPs) which regulate quorum-sensing dependent virulence in this pathogen, or epitopes from SA toxins and leukocidins. These VLPs may be used to provide immunogenic compositions and efficacious vaccines. In a mouse model of SA dermonecrosis, vaccination with AIP-containing VLPs or SA toxin-containing VLPs induces protective immunity to limit the pathogenesis of SA infection and promote bacterial clearance.
-
8.发明申请PROTOCELLS AND THEIR USE FOR TARGETED DELIVERY OF MULTICOMPONENT CARGOS TO CANCER CELLS 审中-公开方案及其用于向癌细胞定向递送多种载体的方法公开(公告)号：US20150164798A1
公开(公告)日：2015-06-18
申请号：US14627739
申请日：2015-02-20
申请人： STC.UNM , SANDIA CORPORATION
发明人： C. Jeffrey Brinker , Carlee Erin Ashley , Xingmao Jiang , Juewen Liu , David S. Peabody , Walker Richard Wharton , Eric Carnes , Bryce Chackerian , Cheryl L. Willman
IPC分类号： A61K9/127 , A61K31/704
CPC分类号： A61K9/127 , A61K9/1277 , A61K9/5115 , A61K9/5123 , A61K31/513 , A61K31/575 , A61K31/704 , A61K33/24 , A61K49/005
摘要： Various embodiments provide materials and methods for synthesizing protocells for use in targeted delivery of cargo components to cancer cells. In one embodiment, the lipid bilayer can be fused to the porous particle core to form a protocell. The lipid bilayer can be modified with targeting ligands or other ligands to achieve targeted delivery of cargo components that are loaded within the protocell to a target cell, e.g., a type of cancer. Shielding materials can be conjugated to the surface of the lipid bilayer to reduce undesired non-specific binding.
摘要翻译： 各种实施方案提供用于合成原细胞以用于向癌细胞靶向递送货物组分的材料和方法。 在一个实施方案中，脂质双层可以与多孔颗粒核心融合以形成原细胞。 脂质双层可以用靶向配体或其他配体进行修饰，以实现载体在原细胞内的货物组分的靶向递送到靶细胞，例如一种类型的癌症。 屏蔽材料可以结合到脂质双层的表面以减少不期望的非特异性结合。
-
公开(公告)号：US20170189503A1
公开(公告)日：2017-07-06
申请号：US15118143
申请日：2015-02-11
CPC分类号： A61K39/0005 , A61K38/10 , A61K45/06 , A61K47/6901 , A61K2039/60 , A61K2039/627 , A61P9/10 , C07K11/00 , C07K14/47 , C12N9/6454 , C12N2795/18123 , C12N2795/18134 , C12N2795/18141 , C12Y304/21061
摘要： A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.
-
公开(公告)号：US09480653B2
公开(公告)日：2016-11-01
申请号：US14627739
申请日：2015-02-20
申请人： STC.UNM , SANDIA CORPORATION
发明人： C. Jeffrey Brinker , Carlee Erin Ashley , Xingmao Jiang , Juewen Liu , David S. Peabody , Walker Richard Wharton , Eric Carnes , Bryce Chackerian , Cheryl L. Willman
IPC分类号： A61K9/56 , A61K9/127 , A61K9/51 , A61K49/00 , A61K31/575 , A61K31/513 , A61K33/24 , A61K31/704
CPC分类号： A61K9/127 , A61K9/1277 , A61K9/5115 , A61K9/5123 , A61K31/513 , A61K31/575 , A61K31/704 , A61K33/24 , A61K49/005
摘要： Various embodiments provide materials and methods for synthesizing protocells for use in targeted delivery of cargo components to cancer cells. In one embodiment, the lipid bilayer can be fused to the porous particle core to form a protocell. The lipid bilayer can be modified with targeting ligands or other ligands to achieve targeted delivery of cargo components that are loaded within the protocell to a target cell, e.g., a type of cancer. Shielding materials can be conjugated to the surface of the lipid bilayer to reduce undesired non-specific binding.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.017 秒)
